Clinical and experimental rheumatology最新文献

{"title":"Comment on: Beyond diagnosis: exploring the significance of IgG4+ plasma cell count through immunostaining in IgG4-related disease.","authors":"Ming-Wei Chiang, Po-Chang Wu","doi":"10.55563/clinexprheumatol/fr0v5l","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/fr0v5l","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated neurosarcoidosis presenting as granulomatous hypophysitis complicated by arginine vasopressin deficiency.","authors":"Victor Ghazi, Bshara Sleem, Georges El Hasbani, Carole Kesrouani, Ali S M Jawad, Imad Uthman","doi":"10.55563/clinexprheumatol/xi4pdx","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/xi4pdx","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel nomogram based on the identification of sTREM2 as a biomarker to predict developing neuropsychiatric systemic lupus erythematosus in lupus patients.","authors":"Xiujiao Wang, Jian Tang, Fengyun Lu, Xue Zhang, Juan Yao, Ping Gu, Mei Sun, Yanyan Wang","doi":"10.55563/clinexprheumatol/1tcgmj","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/1tcgmj","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to identify potential biomarkers and construct a nomogram able to predict the development of neuropsychiatric systemic lupus erythematosus (NPSLE) among SLE patients.</p><p><strong>Methods: </strong>Using bioinformatics analysis, TREM2 was identified as an upregulated gene in NPSLE, participating in various pathological pathways of NPSLE. This study included 80 NPSLE patients and three matched SLE controls with no neuropsychiatric events (non-NPSLE controls) for each of the NPSLE patients. Both serum and cerebrospinal fluid (CSF) concentrations of soluble TREM2 (sTREM2) were assessed. The diagnostic capability of sTREM2 for NPSLE was evaluated using the receiver-operating characteristic curve (ROC curves). The study subsequently integrated a substantial volume of clinical data. Following missing data imputation, patients were randomly allocated to either the training set or the validation set. The Boruta algorithm and Multiple analyses were utilized for constructing the nomogram. Diagnostic performance was assessed using ROC curves, the Hosmer-Lemeshow test, and clinical decision curves.</p><p><strong>Results: </strong>sTREM2 levels were notably elevated in both serum and CSF of NPSLE patients compared to non-NPSLE controls. Serum TREM2 concentrations correlated with NPSLE severity and neuropsychiatric state. Notably, higher SLE Disease Activity Index (SLEDAI), increased systemic lupus international collaborating clinics (SLICC)/ACR damage index (SDI), prolonged activated partial thromboplastin time (APTT), a higher serum B cells, and elevated serum sTREM2 levels emerged as significant predictors for NPSLE.</p><p><strong>Conclusions: </strong>sTREM2 presents as a promising biomarker for NPSLE diagnosis. The nomogram that includes serum sTREM2 level as one of the predictors is effective for distinguishing NPSLE from non-NPSLE patients.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADAMTS13 and insulin resistance in systemic sclerosis patients.","authors":"Iván Ferraz-Amaro, Zena Ibrahim-Achi, Antonia de Vera-González, Mónica Renuncio-García, Esther F Vicente-Rabaneda, J Gonzalo Ocejo-Vinyals, Santos Castañeda, Miguel Ángel González-Gay","doi":"10.55563/clinexprheumatol/az2scd","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/az2scd","url":null,"abstract":"<p><strong>Objectivers: </strong>To investigate the complex interplay between autoimmune disorders, metabolic dysfunction, and vascular health, we assessed the relationship between ADAMTS13, systemic sclerosis-scleroderma (SSc), and insulin resistance.</p><p><strong>Methods: </strong>A cross-sectional study was conducted involving 81 individuals diagnosed with SSc and 76 healthy age- and sex-matched controls. Comprehensive clinical and laboratory characterisations were performed for both groups. Serum levels of ADAMTS13, standard lipid profiles, and indices of insulin resistance were assessed in all participants. To determine whether ADAMTS13 serum levels differed significantly between SSc patients and healthy controls, as well as to examine the relationship between ADAMTS13 values, disease characteristics, and cardiometabolic features, multivariable linear regression analyses were performed.</p><p><strong>Results: </strong>Serum ADAMTS13 levels were significantly decreased in patients with SSc compared to healthy controls after multivariable analysis. A significant negative correlation was observed between C-reactive protein levels and circulating ADAMTS13 levels. However, disease characteristics, including pulmonary, articular, and cutaneous manifestations, did not show significant associations with ADAMTS13 values. Regarding cardiometabolic features, ADAMTS13 levels demonstrated a significant positive association with indices of insulin resistance, a relationship not observed in the control group.</p><p><strong>Conclusions: </strong>ADAMTS13 serum levels are decreased in patients with SSc. Additionally, a positive correlation exists between ADAMTS13 levels and insulin resistance in SSc.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of serum myeloperoxidase with metabolic syndrome and adverse lipid profiles in scleroderma patients.","authors":"Iván Ferraz-Amaro, Zena Ibrahim-Achi, Antonia de Vera-González, Mónica Renuncio-García, Esther F Vicente-Rabaneda, J Gonzalo Ocejo-Vinjals, Santos Castañeda, Miguel Ángel González-Gay","doi":"10.55563/clinexprheumatol/nuevmp","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/nuevmp","url":null,"abstract":"<p><strong>Objectives: </strong>Plasma myeloperoxidase (MPO) levels have been associated with cardiovascular disease in the general population. However, their relationship to cardiovascular manifestations in systemic sclerosis (SSc) remains unexplored. This study aims to investigate the association between circulating MPO and SSc disease characteristics, incorporating a comprehensive assessment of lipid profiles, carotid atherosclerosis, and metabolic syndrome.</p><p><strong>Methods: </strong>This cross-sectional study encompassed 81 individuals with confirmed systemic sclerosis (SSc). All SSc patients underwent a complete clinical evaluation. Serum MPO levels and lipid profiles were assessed. To elucidate potential associations between MPO and both SSc-specific manifestations and cardiometabolic parameters, we employed multivariable linear regression analyses.</p><p><strong>Results: </strong>Disease characteristics, including SSc subtype (diffuse or limited), Rodnan skin score, and the presence of visceral involvement (e.g., pulmonary, or other organ involvement) and autoantibody profiles, showed no correlation with MPO levels. However, significant and positive associations were observed, after multivariable adjustment, between MPO values and the presence of metabolic syndrome, LDL: HDL cholesterol ratio, non-HDL cholesterol, apolipoprotein B levels, apolipoprotein B:A1 ratio, and the atherogenic index.</p><p><strong>Conclusions: </strong>Circulating MPO levels do not correlate with specific SSc disease manifestations. However, higher MPO values are associated with the presence of metabolic syndrome and an unfavorable lipid profile in patients with this condition.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive analysis of trends and inequalities in rheumatoid arthritis burden among women of childbearing age: insights from the Global Burden of Disease study 2021.","authors":"Cun Li, Shaohui Zong","doi":"10.55563/clinexprheumatol/r9rruc","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/r9rruc","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the trends and inequalities in the burden of rheumatoid arthritis (RA) among women of childbearing age (WCBA) and projects future trends at the global, regional, and national levels.</p><p><strong>Methods: </strong>Data on RA prevalence, incidence, disability-adjusted life years (DALYs), and deaths for WCBA were sourced from the Global Burden of Diseases Study 2021. Percentage change (PC), estimated annual percentage change (EAPC), and the ARIMA model were used to analyse trends and project the burden through 2050.</p><p><strong>Results: </strong>In 2021, the global prevalence, incidence, and DALYs cases of RA among WCBA were 4.45 million, 326.6 thousand, and 650.75 thousand, respectively, with significant increases since 1990 (PC: 88%, 68%, and 71%). Over the past 32 years, global rates for prevalence, incidence, and DALYs have all risen, with EAPC values of 0.89 (95% UI: 0.87-0.92), 0.54 (95% UI: 0.51-0.56), and 0.61 (95% UI: 0.57-0.64), respectively. Death cases and rates have decreased globally and in most regions. Among the five Socio-Demographic Index (SDI) regions, the high Socio-Demographic Index (SDI) region reported the highest rates of RA burden. By age, older age groups had higher prevalence, incidence, and DALYs, with the 45-49 age group showing the highest incidence in 2021 (59.22 thousand cases, rate of 25.13 per 10,000). However, younger groups, particularly those aged 15-19, experienced the fastest incidence growth (EAPC 0.64). By 2050, RA prevalence and DALYs rates are projected to rise to 266.34 and 37.63 per 100,000, while incidence will stabilise and deaths will continue to decline.</p><p><strong>Conclusions: </strong>The RA burden among WCBA has significantly increased over the past 32 years, with a notable shift in risk towards younger populations. Higher SDI regions bore a disproportionately greater burden. These findings emphasise the need for increased investments and targeted RA interventions for WCBA, supporting the achievement of WHO's Sustainable Development Goal 3.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-level laser therapy in knee osteoarthritis: a narrative review.","authors":"Xinyu Zhao, Xinyu Lou, Bing Wu, Haocheng Du, Lin Li, Qiusheng Zheng, Xin Guo, Weibo Xiao, Song Xue, Xintao Zhang","doi":"10.55563/clinexprheumatol/muqrbi","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/muqrbi","url":null,"abstract":"<p><p>Knee osteoarthritis (KOA) is a degenerative joint disease that affects the entire knee joint, commonly seen in the elderly, and has shown an increasing trend toward younger populations in recent years. Its main symptoms include pain, swelling, stiffness, and limited mobility; besides, severe cases can lead to disability and complete loss of function.KOA can also lead to psychological issues such as depression and anxiety, posing substantial burdens on patients, families, and society. The current treatment options include physical therapy, medications, and other conservative methods, or surgical treatment. Notably, low-level laser therapy (LLLT) is a non-invasive and safe physical treatment that has been proven to be effective for various conditions affecting the musculoskeletal, nervous, and dermatological systems. Its non-invasive nature avoids the trauma and pain associated with surgery, and it avoids potential side effects of medication. Due to its convenience, safety, and effectiveness, LLLT has been widely recognised as a strategy for treating KOA. This review comprehensively examines the mechanisms of LLLT, including its capacity to modulate synovial macrophage polarisation and regulate the expression of inflammatory factors. It also provides an in-depth analysis of the clinical efficacy of LLLT as a standalone treatment or in conjunction with other therapeutic modalities for KOA patients, drawing on evidence from cellular, animal, and patient studies over recent decades. The aim is to offer robust theoretical support for the treatment of KOA.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study.","authors":"Olga Katsouli, Philippos Orfanos, Vasileios Lainis, Panagiota Katsouli, Gerasimos Kapellos, Panayiotis G Vlachoyiannopoulos","doi":"10.55563/clinexprheumatol/5kr6kk","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/5kr6kk","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the survival of the first biological disease-modifying anti-rheumatic drug (bDMARD) in a Greek rheumatoid arthritis (RA) cohort and determine factors influencing drug retention rates.</p><p><strong>Methods: </strong>Patients from the Pathophysiology Clinic of LAIKON University Hospital who received their first bDMARD were stratified into anti-tumour necrosis factor (anti-TNF) and non-anti-TNF groups, and whether an event occurred. An event was defined as discontinuation due to inefficacy or adverse event (AE), including severe infections. Drug survival curves were calculated using the Kaplan-Meier method. Analysis was performed using t-tests, chi-square tests, and Cox proportional hazards in STATA, with a 5% significance level.</p><p><strong>Results: </strong>We included 724 patients, mostly females (79%), with a median age of 48.6 ±15.7 years at diagnosis. More than half were positive for RF and/or ACPA, with a baseline DAS28-ESR of 4.9 ±1.5. The most used anti-TNFs were etanercept (n=261), infliximab (n=177), adalimumab (n=148), while rituximab (RTX, n=40) was the most used non-anti-TNF. RTX recipients experienced one-half of the events compared to those in the anti-TNF group (IRR 0.52, 95%CI: 0.27 to 0.92). After 276 months, 223 patients discontinued treatment due to inefficacy and 187 due to AEs. Most withdrawals (73.3%) occurred within the first 50 months regardless of cause. RTX was found to be protective against treatment failure, while both RF and ACPA positivity were identified as potential risk factors for discontinuation due to either failure or AE.</p><p><strong>Conclusions: </strong>Only 26.7% of patients remained on first bDMARD after 50 months, with those receiving RTX less likely to discontinue for any reason. RF and/or ACPA positivity could be potential risk factors for discontinuation due to AEs or inefficacy.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 psychological condition in systemic lupus erythematosus patients: a prospective observational study.","authors":"Jingyi Wu, Lijuan Zhang, Zhuochao Zhou, Yaping Wu, Yue Sun, Fan Wang, Jialin Teng, Honglei Liu, Xiaobing Cheng, Yutong Su, Hui Shi, Qiongyi Hu, Jianfen Meng, Huihui Chi, Jinchao Jia, Tingting Liu, Mengyan Wang, Jian Li, Huiping Zhong, Chengde Yang, Junna Ye","doi":"10.55563/clinexprheumatol/2uqnsn","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/2uqnsn","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the post-COVID-19 psychological condition of systemic lupus erythematosus (SLE) patients and the internal relationship between psychiatric symptoms.</p><p><strong>Methods: </strong>A total of 619 SLE patients were included in this observational study, with 493 diagnosed with COVID-19 and 126 remaining uninfected. Visual analogue scale (VAS), Multi-dimensional Fatigue Inventory (MFI), Patient Health Questionnaire-9 (PHQ-9), and Pittsburgh Sleep Quality Index (PSQI) were utilised to assess pain, exhaustion, depression, and sleep quality, respectively. Network analysis found the core symptoms and bridge symptoms. Logistic regression was utilised to assess the impact of COVID-19 symptoms on later psychiatric symptoms.</p><p><strong>Results: </strong>COVID-19 infected SLE patients had higher levels of pain, 'General Fatigue' (GF), PHQ-9, and PSQI ratings compared to others (p=0.006, 0.027, 0.003, and 0.049, respectively). The infected SLE patients' network of depression, fatigue, and sleep issues identified GF and 'Feeling down, hopeless' (PHQ2) as core symptoms with the greatest expected influence of 1.20. The symptoms 'Trouble sleeping' (PHQ3), GF and 'Daytime dysfunction' (DD) were bridge symptoms with greatest bridge expected influence of 0.72, 0.56 and 0.53, respectively. COVID-19 symptoms such as shortness of breath, weakness, and joint discomfort were linked to post-COVID-19 psychological condition.</p><p><strong>Conclusions: </strong>Our study demonstrated a worse long-term mental status in COVID-19 infected SLE patients. Early screening and specific therapies might help prevent mental issues in SLE patients.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum connective tissue growth factor is aberrantly expressed in idiopathic inflammatory myopathy.","authors":"Leiyi Yang, Hongjiang Liu, Qibing Xie, Geng Yin","doi":"10.55563/clinexprheumatol/2n2sag","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/2n2sag","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}